格卡瑞韦联合哌仑他韦在无肝硬化HCV基因1-6型患者中取得高应答率
SURVEYOR-I和SURVEYOR-II两项II期开放标签多中心剂量探索试验纳入449例无肝硬化慢性HCV基因1-6型患者,评估格卡瑞韦联合哌仑他韦8周或12周治疗的疗效与安全性。12周治疗在基因1、2、3、4-6型患者中SVR12分别为97-100%、96-100%、83-94%、100%;8周治疗(300mg格卡瑞韦+120mg哌仑他韦)在基因1、2、3型患者中SVR12为97-98%且无病毒学失败。治疗耐受性良好。
要点
- 12周格卡瑞韦联合哌仑他韦在基因1、2、4-6型患者中SVR12达96-100%,基因3型为83-94%。
- 8周300mg格卡瑞韦+120mg哌仑他韦在基因1、2、3型患者中SVR12为97-98%,无病毒学失败。
- 3例(0.7%)患者因不良事件停药,多数不良事件为轻度(1级),未观察到谷丙转氨酶超过基线后升高。
核心结论
- 格卡瑞韦联合哌仑他韦耐受性良好,在无肝硬化HCV基因1-6型患者中经8周或12周治疗取得高持续病毒学应答率。
研究设计与样本
- SURVEYOR-I和SURVEYOR-II为II期、开放标签、多中心、剂量探索试验,纳入慢性HCV基因1-6型感染且既往未治疗或曾接受聚乙二醇干扰素联合利巴韦林治疗的患者。
- 患者接受每日一次不同剂量的格卡瑞韦联合哌仑他韦,联合或不联合利巴韦林,疗程8周或12周,主要疗效终点为治疗后第12周持续病毒学应答率(SVR12)。
- 共449例患者接受不同剂量格卡瑞韦联合哌仑他韦治疗,基因1、2、3、4-6型感染者分别占25%、29%、39%、8%。
主要发现
- 12周治疗在基因1、2、3、4-6型患者中SVR12分别为97-100%、96-100%、83-94%、100%。
- 8周300mg格卡瑞韦联合120mg哌仑他韦治疗基因1、2、3型患者,SVR12为97-98%,无病毒学失败。
- 3例(0.7%)患者因不良事件停药,多数不良事件为轻度(1级),未观察到谷丙转氨酶超过基线后升高。
关键数值与推荐
- 主要疗效终点为治疗后第12周持续病毒学应答率(SVR12)。
- 8周治疗方案为300mg格卡瑞韦联合120mg哌仑他韦,每日一次。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection. METHODS: SURVEYOR-I and SURVEYOR-II were phase II, open-label, multicenter, dose-ranging trials including patients with chronic HCV genotype 1-6 infection who were either previously untreated or treated with pegylated interferon plus ribavirin. Patients received once-daily glecaprevir plus pibrentasvir at varying doses with or without ribavirin for 8 or 12weeks. The primary efficacy endpoint was the percentage of patients with a sustained virologic response at post-treatment week 12 (SVR12). RESULTS: Of the 449 patients who received varying doses of glecaprevir plus pibrentasvir, 25%, 29%, 39%, and 8% had HCV genotype 1, 2, 3, and 4-6 infection, respectively. Twelve-week treatment achieved SVR12 in 97-100%, 96-100%, 83-94%, and 100% in genotypes 1, 2, 3, and 4-6, respectively. Eight-week treatment with 300mg glecaprevir plus 120mg pibrentasvir in genotype 1-, 2-, or 3-infected patients yielded 97-98% SVR12 with no virologic failures. Three (0.7%) patients discontinued treatment due to adverse events; most events were mild (grade 1) in severity. No post-nadir alanine aminotransferase elevations were observed. CONCLUSIONS: Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virologic response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-week treatment durations. LAY SUMMARY: The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection. This article describes results from two phase II trials investigating a range of doses at treatment durations of 8 or 12weeks in 449 patients without cirrhosis. Efficacy of the optimal dose, as determined by rates of sustained virologic response at post-treatment week 12, ranged from 92%-100%; treatment was well tolerated and significant laboratory abnormalities were rare. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT02243280 and NCT02243293. http://www.clinicaltrials.gov/show/NCT02243280, http://www.clinicaltrials.gov/show/NCT01939197.
引用
- Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017. PMID: 28412293. doi:10.1016/j.jhep.2017.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。